Synapse Open Synapse
Biology

J&J earnings set ‘negative tone’; Shkreli vs. the FTC

BioPharma Dive · · 2 min read

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

Latest from BioPharma Dive